Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP05 versus Lucentis in wet age-related macular degeneration
2021-000590-93Phase 3Active
- Sponsor
- CuraTeQ Biologics
- Start
- Feb 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing BP05 with Lucentis (2 arms). Primary endpoint: Change in best corrected visual acuity at Week 8. Started Feb 2023; status: active.
02
Drugs
BP05ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2021-000590-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000590-93.